The key updates at Probiodrug’s FY2017 results were the overall strategy for the Phase IIb programme and the detailed design of the European study for lead compound PQ912, a small molecule glutaminyl cyclase ("QC") inhibitor in development for Alzheimer’s disease (“AD”). The trial design incorporates the draft guidance provided by the FDA and the EMA in February 2018 for the development of drugs in early AD patients, with a focus on detecting changes in cognition thus building on the clinical da ....
10 Apr 2018
Lifting the veil on Phase IIb design
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Lifting the veil on Phase IIb design
Vivoryon Therapeutics N.V. (0R3M:LON) | 0 0 0.4% | Mkt Cap: 102.2m
- Published:
10 Apr 2018 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
14
The key updates at Probiodrug’s FY2017 results were the overall strategy for the Phase IIb programme and the detailed design of the European study for lead compound PQ912, a small molecule glutaminyl cyclase ("QC") inhibitor in development for Alzheimer’s disease (“AD”). The trial design incorporates the draft guidance provided by the FDA and the EMA in February 2018 for the development of drugs in early AD patients, with a focus on detecting changes in cognition thus building on the clinical da ....